Clinicopathologic Prognostic Factors in NMIBC for Recurrence & Progression

Praveen Gopi *

Department of Urology, Government Medical College, Thiruvananthapuram, Kerala, India.

S. Darsan

Department of Urology, Government Medical College, Thiruvananthapuram, Kerala, India.

R. Sunil

Department of Urology, Government Medical College, Thiruvananthapuram, Kerala, India.

Rustam Singh Kaurav

Department of Urology, Government Medical College, Thiruvananthapuram, Kerala, India.

Vasudevan Sambu Potty

Department of Urology, Government Medical College, Thiruvananthapuram, Kerala, India.

*Author to whom correspondence should be addressed.


Abstract

Introduction: Transitional cell carcinoma (TCC) accounts for more than 90% of all the bladder cancers out of which 70% are non-muscle invasive bladder cancer (NMIBC) at diagnosis. The high rate of recurrence and progression following transurethral bladder resection of tumor makes the follow up essential as well as crucial in detecting early recurrence of tumor. In our study, we investigated the predictive value of various factors for recurrence and disease progression which could help in identifying patients for early definitive treatment.

Objectives: To determine the predictive factors of recurrence and progression of NMIBC managed in a single centre.

Methods: Retrospective study of 256 patients of NMIBC after TURBT was done to review the factors related with recurrence and progression. Bivariable analysis (Chi square test &Mann U Whitney test) and multivariable binary logistic regression were used to identify predictors of recurrence and progression.

Results: On multivariate analysis, patients with tumor-size >3 cm and multiple tumors were found to have 1.7 times and 3 times greater odd of recurrence respectively as compared to patients with tumor size < 3cm and single tumor. Patients diagnosed with T1 stage and multiple lesions were found to have 1.9 times and 1.8 times greater odds of progression respectively as compared to patients with Ta stage and single lesion. With regard to quantitative factors, none of them were significantly associated for prediction for recurrence and progression.

Conclusion: Multiple tumors had increased risk for the development of both recurrence and disease progression. Size of tumor >3 cm is a risk factor for the development of recurrence and T1 stage was found to be a risk-factor for progression of the disease.

Keywords: Bladder, cancer, recurrence, progression, smoking


How to Cite

Gopi , P., Darsan , S., Sunil , R., Kaurav , R. S., & Potty , V. S. (2023). Clinicopathologic Prognostic Factors in NMIBC for Recurrence & Progression. Asian Journal of Research and Reports in Urology, 6(1), 69–75. Retrieved from https://journalajrru.com/index.php/AJRRU/article/view/94

Downloads

Download data is not yet available.

References

Siegel R, Ma J, Zou Z, Jemal A CA. Cancer statistics, 2014 Cancer J Clin. 2014 Jan-Feb;64(1):9-29.

Consolidated report of population-based cancer registries 2001-2004. National Cancer Registry Programme (Indian Council of Medical Research), Bangalore. 2006;31-32

Siegel RL, Miller KD, Jemal A CA. Cancer statistics, 2015. Cancer J Clin. 2015 Jan-Feb;65(1):5-29. [PubMed]

Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder BJU Int. 2004 Jul;94(1):18-21.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer Eur Urol. 2013 Feb;63(2):234-41

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials .Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7.

Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: A proposed prognostic index.Br J Urol. 1998;81:692–8.

Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer:report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).J Urol. 1989;142:284–8.

Ray D, Mondal R, Achryya S, De S, Mondal S. A retrospective study of bladder cancer and the impact of age, sex and smoking habits with related clinicopathological correlations in the tribal population of Bankura, WB, India. IOSR J Dent Med Sci. 2013;10:29-32.

Rawal S. Bladder cancer: A difficult problem? Indian J Urol. 2008;24:60-62

Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin:a multivariate analysis of factors affecting tumor progression.J Urol. 1989;141:22–9.

Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem EI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: Analysis of prognostic factors and construction of a predictive index. BJU Int. 2003;92:393–9

Fernandez-Gomez J, Madero R, Solsona E etal. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.Eur Urol. 2011;60:423–30

Dalesio O, Schulman CC, Sylvester R etal. Prognostic factors in superficial bladder tumors.A study of the European Organization for Research on Treatment of Cancer:Genitourinary Tract Cancer Cooperative Group. J Urol. 1983;129: 730–3.

Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations.The Dutch South-Eastern Urological Collaborative Group.Br J Urol. 1994;73:403–8.

Chang YH, Chuang CK, Pang ST, Wu CT, Chuang KL, Liao SK. 'The impact of regular biopsy in the first cystoscopic follow-up and Other predictors on the recurrence of superficial bladder tumor, Chang Gung Med J. 2010;33(2):174-81.

Khan MK, Ahmed, Raza SJ.'Factors affecting recurrence and progression of high grade non-invasive bladder cancer treated by intravesical BCG,' Pak J Med Sci. 2014;30(2):326-330.

Sylvester RJ, van der Meijden AP, Oosterlinck W etal. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–77.